Forbion
Venture capitalAmsterdam · Pre-Seed–Late Stage · 1 people tracked
Investment thesis
Forbion invests in groundbreaking biotech and sustainable solutions with a focus on human and planetary health. The firm integrates ESG principles into its investment approach, prioritizing patient impact, societal benefits, and sustainability outcomes. Portfolio spans human health (rare genetic diseases) and planetary health (sustainable resource extraction and environmental solutions).
Source: firm website, verified Jul 21, 2026.
Team · 1 people
from the firm's websiteWhat they invest in
from 4 of 7 portfolio companiesBiotech ×3Medical Devices ×2AI & Machine Learning ×1Cybersecurity ×1Deep Tech ×1Enterprise Software ×1SaaS ×1
HQs:Switzerland×1Colombia×1
Investments · 7 tracked
founders shown can be your intro pathGate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.
BiotechDeep TechMedical Devices
Jordi Mata-Fink(Chief Executive Officer, Co-Founder)Raman Talwar(Chief Technology Officer, Co-Founder)Pat Sharp(Scientific Founder)
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)
Developing therapies for patients with severe rare genetic diseases.
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)
Pioneering efficient, plant-based metal farming for global metal extraction.
A fully integrated gene therapy company developing innovative therapeutics including vectorized antibodies for CNS and somatic disorders, with focus on muscle diseases.
Frequently asked questions
- What stage does Forbion invest at?
- Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Forbion focus on?
- Forbion focuses on Biotech, Climate Tech, Impact & Social Good.
- Where is Forbion located?
- Forbion is headquartered in Amsterdam, NL.
Images
Similar investors
Octopus Ventures is a pan-European early-stage venture capital firm that invests from pre-seed through Series A and beyond, with pre-seed investments typically at £100k and later-stage investments starting at £1 million.
Novo Holdings is a holding and investment company managing the assets of the Novo Nordisk Foundation, one of the world's largest enterprise foundations. The firm invests in life science companies across all development stages and manages a diversified portfolio including equities, bonds, real estate, infrastructure, and private equity.
B Capital is a venture capital firm managing $12+ billion in assets under management with 200+ early to late-stage portfolio companies across 9 global locations. The firm operates dedicated stage-based funds supporting entrepreneurs throughout the company-building lifecycle.
500 Global's Sustainable Growth practice designs and implements sovereign-aligned strategies that unlock resilient, inclusive, and sustainable economic growth across the Global Majority—Asia, Africa, Latin America, and the Middle East. The practice bridges public priorities and private capital through ecosystem development, blended finance, and localized innovation programs addressing health, agriculture, gender, climate, and education.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.